Overview
Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
Status:
Completed
Completed
Trial end date:
2016-12-01
2016-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Biota Pharma Europe Limited
Criteria
Inclusion Criteria:1. Healthy male or female
2. Between 18 to 50 years old
3. Body mass index of 18 to 30 kg/m2
Exclusion Criteria:
1. Acute or chronic medical illness
2. Abnormal lung function Positive for HIV, Hepatitis B or C
3. Any significant abnormality of the nose or nasopharynx